Here’s an article detailing the news from Business Wire French Language News:
Median Technologies Secures Significant Funding to Accelerate eyonis® LCS Commercialization in the United States
Paris, France – July 21, 2025 – Median Technologies, a leading innovator in medical imaging and artificial intelligence, has announced a significant financial development poised to propel the commercialization of its flagship product, eyonis® LCS, in the United States. This news follows the company’s recent securing of a financial agreement for up to €37.5 million with the European Investment Bank (EIB).
In conjunction with this substantial EIB backing, Median Technologies is launching a capital increase of €22.0 million. This strategic move is designed to fuel the ambitious market entry of eyonis® LCS in the crucial United States market. Furthermore, the newly raised capital will be instrumental in financing other key areas of the company’s development.
The eyonis® LCS platform represents a significant advancement in the field of medical imaging analysis. By leveraging cutting-edge artificial intelligence, it aims to enhance the detection and monitoring of lung cancer, a disease that continues to pose a substantial global health challenge. The company’s focus on the US market, the largest healthcare market globally, underscores its commitment to making this innovative technology accessible to a broad patient population and healthcare providers.
The dualpronged financial strategy – the EIB agreement and the capital increase – demonstrates a strong vote of confidence in Median Technologies’ vision and its technological capabilities. This infusion of capital is expected to empower the company to build out its sales and marketing infrastructure in the US, navigate regulatory pathways, and ultimately ensure the successful adoption of eyonis® LCS.
Further details regarding the specific allocation of the capital increase beyond the US commercialization of eyonis® LCS are anticipated to be revealed as the company progresses. This development marks an exciting chapter for Median Technologies as it aims to make a meaningful impact on lung cancer diagnosis and patient care through its pioneering AI solutions.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘Après la signature d’un accord financier allant jusqu’à 37,5 millions d’euros avec la BEI, Median Technologies lance une augmentation de capital de 22,0 millions d’euros pour soutenir la commercialisation d’eyonis® LCS aux Etats-Unis et financer …’ at 2025-07-21 20:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.